INTRODUCTION {#s1}
============

Antiplatelet agents are one of the cornerstones of stroke prevention and are widely utilized in the setting of primary stroke prevention, secondary stroke prevention, and neuroendovascular device--related stroke prevention. Their utility is highlighted in several seminal works, which underscore their importance in preventing brain-related ischemia from a diverse array of pathologic processes ([@MCS003731BONC28]; [@MCS003731BONC53]; [@MCS003731BONC13]; [@MCS003731BONC9]; [@MCS003731BONC47]). Although these drugs are overwhelmingly effective from a population-based standpoint in clinical studies, their efficacy in any single patient may be varied based on a multitude of factors, primarily relating to genotype.

Aspirin (acetylsalicylic acid), the most common antiplatelet drug in use, has a long appreciated resistance phenomenon ([@MCS003731BONC25]; [@MCS003731BONC36]). With respect to neurovascular disease, patients who experience recurrent ischemia despite adherence to aspirin therapy have been termed aspirin "failures" ([@MCS003731BONC29]; [@MCS003731BONC5]). The addition of a second antiplatelet agent likely increases efficacy, although the mechanism of polytherapy\'s effect is not always clear. Does an additional agent act synergistically to further decrease already diminished platelet reactivity, or does it simply provide effective antiplatelet activity when an individual is a nonresponder to aspirin? In the latter scenario, continuation of aspirin therapy would provide no benefit while exposing the patient to potential adverse effects, such as gastrointestinal ulcer.

Clopidogrel, another commonly utilized drug, is well known for exhibiting a resistance phenomenon, which is associated with adverse clinical events ([@MCS003731BONC48]; [@MCS003731BONC73]). The prevalence of clopidogrel resistance ranges from 4% to 44%, depending on the population studied ([@MCS003731BONC26]). The often essential nature of these medications mandates that an effective antiplatelet response is achieved, as failure could result in substantial morbidity or mortality.

Currently, many patients on dual antiplatelet therapy undergo platelet function testing prior to neurointerventional procedures using a variety of commercially available assays. There are several limitations to many of the currently available platelet function assays, including variability in results across assays, dependence of results on patient hematocrit and platelet counts, and high costs. No high-level evidence exists to support or refute the use of platelet function testing on neurovascular clinical practice. Additionally, the variable clinical practices inspired by the results of these tests have not been well studied.

The ability to better understand the relationship between genotype and drug activity may be able to improve stroke prevention paradigms for neurologists and neurointerventionalists alike. With the ability to perform rapid, accurate, and increasingly lower cost genomic testing, the opportunity to select a specific antiplatelet therapy based on a patient\'s genotype is approaching clinical practice. The potential benefits of genotype-informed antiplatelet selection include both improved efficacy (stroke prevention) and reduced toxicity (bleeding complications). In this review, we highlight the common and rare genomic variants known to be associated with resistance to drugs most frequently used in clinical practice. From there, we explore future directions of how genomic testing can be integrated into clinical practice to improve stroke prevention.

DATA SYNTHESIS {#s2}
==============

Aspirin, clopidogrel, ticagrelor, ticlopidine, and prasugrel were selected for study on the basis of being commonly used in clinical practice. The PharmGKB database (<https://www.pharmgkb.org>; accessed Oct 22 2018) was mined for variants associated with these drugs. Reports were cross-referenced with original source manuscripts. Annotated variants were then sorted based on levels of evidence as previously described ([@MCS003731BONC74]). Only the highest quality of annotations (levels 1 and 2) were used for reporting purposes. If high-quality annotations did not exist, then the next two levels of quality were reported. Insufficient genotype data were available to report for ticlopidine. Variants and citations are provided as representative examples and may not represent all information that is available on an allele or be comprehensive of all candidate alleles.

ANTIPLATELET AGENTS {#s3}
===================

Aspirin {#s3a}
-------

Aspirin (acetylsalicylic acid) is an ubiquitous first-generation antiplatelet agent with a long clinical prescribing history. Its primary mechanism of antiplatelet action is attributed to blocking the synthesis of thromboxane A2 from arachidonic acid by irreversible inhibition of prostaglandin G/H synthase 1 (PTGS1, also known as cyclooxygenase 1) within platelets ([@MCS003731BONC68]). Although effective, there are certain individuals resistant to aspirin\'s effects. In patients with cardiovascular disease, it has been reported that about 5% of patients are nonresponders to aspirin based on ex vivo testing ([@MCS003731BONC24], [@MCS003731BONC25]), with up to 23% considered semiresponders ([@MCS003731BONC24]). Clinically, the most concerning aspect of aspirin resistance is an increased risk of adverse events compared to patients who are aspirin sensitive, a phenomenon that has been shown in prospective analyses of cardiovascular patients ([@MCS003731BONC25]; [@MCS003731BONC45]; [@MCS003731BONC8]).

Resistance to any antiplatelet agent may be multifactorial. Impaired bioavailability, drug--drug interactions, up-regulation of nonplatelet sources of thromboxane biosynthesis, increased platelet turnover, and patient noncompliance are thought to be mechanisms of aspirin resistance ([@MCS003731BONC27]). Although these mechanisms likely play a role in a patient\'s response to aspirin, genetic variability in *PTGS1* and other genes has also been correlated with functional aspirin resistance (see [Table 1](#MCS003731BONTB1){ref-type="table"}).

###### 

Aspirin---variants

  References                                                                                            Level  Population                     Gene        Variant (GRCh38)   Notes
  ---------------------------------------------------------------------------------------------------- ------- ------------------------------ ----------- ------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@MCS003731BONC71]; [@MCS003731BONC39]                                                                 2b    Acute coronary syndrome        *PTGS1*     rs10306114         Patients with the AA genotype who are treated with aspirin may have a decreased, but not absent, risk for nonresponse to aspirin as compared to patients with the AG or GG genotype.
  [@MCS003731BONC49]; [@MCS003731BONC17]                                                                 2b    Healthy volunteer              *GP1BA*     rs6065             Patients with the CC genotype may have an increased risk for aspirin resistance as compared to patients with the CT or TT genotype.
  [@MCS003731BONC33]; [@MCS003731BONC46]; [@MCS003731BONC43]; [@MCS003731BONC37]; [@MCS003731BONC50]     2b    PCI; acute coronary syndrome   *CYP2C19*   rs4244285          Patients with the \*2/\*2 diplotype may have an increased incidence of hemorrhage, stroke, and an overall worse response to clopidogrel and aspirin, such as decreased platelet reactivity, as compared to patients with the \*1/\*1, \*1/\*17, \*17/\*17, \*1/\*2 diplotypes. However, this has been contradicted in some studies.

(PCI) Percutaneous coronary intervention, (GRCh38) Genome Reference Consortium Human Build 38, (ACS) acute coronary syndrome, (CAD) coronary artery disease.

Clopidogrel (Plavix) {#s3b}
--------------------

Clopidogrel is another commonly prescribed antiplatelet drug, with generic formulations available in the United States and many other countries. The ingested form is a prodrug and requires two sequential oxidative steps within the liver to achieve biological activity via an active metabolite, which consists of irreversible inhibition of the platelet P2Y12 adenosine diphosphate receptor.

Although it is not typically considered a first-line agent for stroke prevention, clopidogrel is often combined with aspirin for dual antiplatelet therapy. Common indications include clinical failure of aspirin monotherapy (e.g., ischemic infarct despite aspirin compliance) and neurovascular stent placement (e.g., cervical carotid or intracranial artery stent). Though clopidogrel is used when there is a perceived increased risk of cerebral ischemia, there is variation in patient responsiveness to this drug, and a fair percentage of the population has some resistance. It has been shown that up to half of individuals may have decreased platelet inhibition with this drug, mostly related to common polymorphisms of *CYP2C19* alleles (see [Table 2](#MCS003731BONTB2){ref-type="table"}; [@MCS003731BONC6]). In fact, the variability of response to this drug is so prevalent, the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline recommends alternative antiplatelet therapy for acute coronary syndrome/percutaneous coronary intervention individuals predicted to be intermediate or poor metabolizers based on genotype, underscoring its clinical relevance ([@MCS003731BONC60]).

###### 

Clopidogrel---variants

  References                                                                                                               Level  Population                                                                                 Gene        Variant (GRCh38)   Notes
  ----------------------------------------------------------------------------------------------------------------------- ------- ------------------------------------------------------------------------------------------ ----------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@MCS003731BONC76]; [@MCS003731BONC62]; [@MCS003731BONC51]; [@MCS003731BONC72]; [@MCS003731BONC38]                        1A    Acute coronary syndrome; acute coronary syndrome undergoing PCI                            *CYP2C19*   rs4986893          Patients with the GG genotype (1) may have increased metabolism of clopidogrel and formation of active drug metabolite, resulting in increased response and (2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA or AG genotype.
  [@MCS003731BONC2]; [@MCS003731BONC63]; [@MCS003731BONC57]; [@MCS003731BONC62]; [@MCS003731BONC58]; [@MCS003731BONC23]     1A    Healthy volunteers; acute coronary syndrome; acute coronary syndrome undergoing PCI; PCI   *CYP2C19*   Multiple           Patients with two functional CYP2C19 alleles (\*1/\*1) (1) may have increased metabolism of clopidogrel and (2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with one or two CYP2C19 loss-of-function alleles (\*2 rs4244285, \*3 rs4986893, \*4 rs28399504, \*5 rs56337013, \*6 rs72552267, \*8 rs41291556).
  [@MCS003731BONC64]; [@MCS003731BONC71]; [@MCS003731BONC32]; [@MCS003731BONC56]                                            1A    PCI; acute coronary syndrome                                                               *CYP2C19*   rs4244285          Patients with the GG genotype (1) may have sufficient metabolism of clopidogrel and increased formation of active drug metabolite and (2) may have a decreased risk for secondary cardiovascular events with clopidogrel as compared to patients with the AA or AG genotype.
  [@MCS003731BONC62]; [@MCS003731BONC51]; [@MCS003731BONC72]                                                                1A    Acute coronary syndrome                                                                    *CYP2C19*   rs28399504         Patients with the AA genotype (1) may have increased metabolism of clopidogrel and (2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG and AG genotype.
  [@MCS003731BONC76]; 22028352; [@MCS003731BONC72]; [@MCS003731BONC67]                                                      1A    Acute coronary syndrome, PCI                                                               *CYP2C19*   rs12248560         Patients with the CC genotype (\*1/\*1) (1) may have decreased activation of clopidogrel, (2) may have a decreased, but not absent, risk for bleeding with clopidogrel as compared to patients with the CT or TT genotype, and (3) may have an increased risk for adverse cardiovascular events as compared to patients with a CT or TT genotype. Other genetic, including CYP2C19 loss-of-function alleles (e.g., \*2 rs4244285,\*3 rs4986893), and clinical factors may also influence a patient\'s risk for bleeding and adverse cardiovascular events.
  [@MCS003731BONC42]; [@MCS003731BONC65]                                                                                    2B    Healthy volunteer                                                                          *CES1*      rs71647871         Patients with the CC genotype who are treated with clopidogrel may have higher on-treatment ADP-induced platelet aggregation and lower levels of clopidogrel active metabolite as compared to patients with the CT or TT genotype.

The CPIC recommendations are supported by several notable clinical studies. A subgroup analysis of more than 10,000 patients in the PLATO trial who underwent genotype analysis for various *CYP2C19* single-nucleotide polymorphisms found that patients on clopidogrel with loss-of-function *CYP2C19* alleles had higher rates of cardiovascular death, myocardial infarction, and stroke at 12 months than those without. In addition, clopidogrel patients with gain of function alleles had higher rates of major bleeding than those without ([@MCS003731BONC72]). Recently, implementation of a genotype-driven prediction model for clopidogrel resistance was shown to reduce cardiovascular events in patients undergoing PCI by nearly threefold ([@MCS003731BONC7]). In addition, data that correlate results of functional assays with clinical outcome, demonstrating the association between decreased platelet inhibition and clinical events, has been published ([@MCS003731BONC48]). Large-scale efforts are underway to identify additional determinants of patient response to clopidogrel by cross-referencing genetic and platelet function data ([@MCS003731BONC3]).

Clopidogrel, perhaps more so than any other drug, has several known nongenetic factors that influence response in any one individual, making interpretation of genetic variation challenging. Several prevalent conditions including diabetes mellitus and renal impairment are associated with blunted responses to clopidogrel ([@MCS003731BONC19]; [@MCS003731BONC4]; [@MCS003731BONC55]). Additionally, several common medications including proton pump inhibitors appear to reduce the antiplatelet effects of clopidogrel through competition for shared metabolic pathways (*CYP2C19*) in the liver ([@MCS003731BONC20], [@MCS003731BONC21]; [@MCS003731BONC30]).

Prasugrel (Effient) {#s3c}
-------------------

Prasugrel is a next-generation antiplatelet agent that inhibits ADP-platelet activation by irreversibly binding to the P2Y12 receptor. Like clopidogrel, the ingested form of the drug needs to be converted to an active metabolite. This occurs both by CYP450-dependent conversion and by carboxylesterase 2-mediated hydrolysis during absorption ([@MCS003731BONC31]; [@MCS003731BONC51]; [@MCS003731BONC14]). In contrast to clopidogrel, prasugrel tends to have a more efficient absorption and is more rapidly converted to its active metabolite. Furthermore, although CYP450 genetic variants exist, many do not have a functional consequence on prasugrel activity ([@MCS003731BONC6]; [@MCS003731BONC51], [@MCS003731BONC52]; [@MCS003731BONC69]). There are isolated reports of prasugrel resistance ([@MCS003731BONC1]; [@MCS003731BONC15]), and preliminary research suggests that polymorphisms in *PEAR1* may contribute to variation in pharmacodynamics response (see [Table 3](#MCS003731BONTB3){ref-type="table"}; [@MCS003731BONC77]; [@MCS003731BONC16]).

###### 

Prasugrel---variants

  Reference(s)                            Level   Population                                                      Gene        Variant (GRCh38)   Notes
  --------------------------------------- ------- --------------------------------------------------------------- ----------- ------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@MCS003731BONC77]                      3       Healthy volunteer                                               *PEAR1*     rs822441           Patients with the CC genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CG or GG genotype.
  [@MCS003731BONC77]                      3       Healthy volunteer                                               *PEAR1*     rs12407843         Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AG or GG genotype.
  [@MCS003731BONC77]                      3       Healthy volunteer                                               *PEAR1*     rs77235035         Patients with the AA genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the AC or CC genotype.
  [@MCS003731BONC10]                      3       Acute coronary syndrome treated with PCI                        *CYP2C19*   rs12248560         Patients with the TT and CT genotype and acute coronary syndrome who are treated with prasugrel may have an increased risk for bleeding as compared to patients with the CC genotype.
  [@MCS003731BONC77]                      3       Healthy volunteer                                               *PEAR1*     rs3737224          Patients with the TT genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CT or CC genotype.
  [@MCS003731BONC77]                      3       Healthy volunteer                                               *PEAR1*     rs822442           Patients with the CC or AC genotype who are treated with prasugrel may have higher levels of platelet aggregation inhibition as compared to patients with the AA genotype.
  [@MCS003731BONC77]                      3       Healthy volunteer                                               *PEAR1*     rs41273215         Patients with the TT genotype who are treated with prasugrel may have lower levels of platelet aggregation inhibition as compared to patients with the CT or CC genotype.
  [@MCS003731BONC10]; [@MCS003731BONC6]   3       Acute coronary syndrome treated with PCI; healthy individuals   *CYP2C19*   rs4244285          Patients with the GG genotype who are treated with prasugrel may have a lower rate of high on-treatment platelet reactivity at 1 mo of treatment as compared to patients with the AG or AA genotype. However, contradictory findings are reported.

Despite the potential advantage of averting resistance phenomenon seen with clopidogrel, the largest randomized trial of prasugrel versus clopidogrel (performed in patients with coronary disease) demonstrates conflicting evidence regarding increased hemorrhagic complications between different subgroups of patients ([@MCS003731BONC75]; [@MCS003731BONC54]).

This trial also demonstrated the feasibility of investigating the genetic underpinnings of platelet functionality and clinical outcome ([@MCS003731BONC52]). Comparison of these drugs for the treatment of patients with neurovascular disease has not been performed, and widespread adoption of prasugrel has not occurred.

Ticagrelor (Brilinta) {#s3d}
---------------------

Ticagrelor is another next-generation antiplatelet agent. Uniquely, the drug does not require in vivo bioactivation in order to reversibly inhibit the P2Y12 receptor ([@MCS003731BONC59]). Still, it undergoes metabolism via CYPP450 3A4 and 3A5 metabolism to generate an equipotent metabolite, AR-C124910XX ([@MCS003731BONC66]; [@MCS003731BONC22]). Ticagrelor has been studied extensively in the cardiovascular literature, and a randomized trial (PLATO) with subgroup analysis of genetic polymorphisms concluded that it is more efficacious at preventing cardiovascular death, myocardial infarction, or stroke than clopidogrel, irrespective of genetic makeup ([@MCS003731BONC72]). Enthusiasm for the drug in stroke prevention in particular was tempered by a head-to-head randomized trial of aspirin and ticagrelor, yielding no difference in the rate of stroke, myocardial infarction, or death in the follow-up period after stroke or transient ischemic attack ([@MCS003731BONC35]).

The influence of genetic polymorphisms on ticagrelor activity is not well studied. A genome-wide association study of the patients with acute coronary syndrome in the above-mentioned PLATO study revealed three loci (*SLCO1B1*, *UGT2B7*, and *CYP3A4*) that potentially influence its pharmacokinetics to a modest degree ([@MCS003731BONC70]). In this limited study, no difference in efficacy or safety was observed based on the variation in ticagrelor levels, leading the authors to conclude that use of ticagrelor does not require genetic testing. Other preliminary studies have identified loci potentially affecting drug levels or activity, with unclear clinical significance (see [Table 4](#MCS003731BONTB4){ref-type="table"}).

###### 

Ticagrelor---variants

  Reference            Level   Population                Gene        Variant (GRCh38)   Notes
  -------------------- ------- ------------------------- ----------- ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@MCS003731BONC70]   3       Acute coronary syndrome   *SLCO1B1*   rs113681054        Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes.
  [@MCS003731BONC70]   3       Acute coronary syndrome   *CYP3A43*   rs62471956         Patients with the GG genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the AA or AG genotypes.
  [@MCS003731BONC70]   3       Acute coronary syndrome   *UGT2B7*    rs61361928         Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype.
  [@MCS003731BONC70]   3       Acute coronary syndrome   *SLCO1B1*   rs4149056          Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes.
  [@MCS003731BONC70]   3       Acute coronary syndrome   *CYP3A4*    rs56324128         Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype.
  [@MCS003731BONC44]   4       Healthy volunteer         *PEAR1*     rs12041331         Patients with the GG genotype may have deceased inhibition of platelet aggregation in response to ticagrelor compared to patients with the AA genotype.
  [@MCS003731BONC44]   4       Healthy volunteer         *PEAR1*     rs12566888         Patients with the TT genotype may have lower maximal platelet aggregation than patients with the GT genotype when taking ticagrelor.
  [@MCS003731BONC44]   4       Healthy volunteer         *PEAR1*     rs4661012          Patients with the TT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to patients with the GG genotype.

DISCUSSION {#s4}
==========

Individual genetic influences have an impact on the pharmacokinetics and pharmacodynamics of antiplatelet agents. Although clopidogrel is one of the most variable in terms of individual response, it remains one of the most frequently prescribed medications for secondary stroke prevention and device-related stroke prevention. Given the limitations of clopidogrel, there is shifting precedence in the cardiology literature from using clopidogrel to using either prasugrel or ticagrelor along with aspirin for dual antiplatelet therapy. A recent joint guideline from the American College of Cardiology/American Heart Association (Level of Evidence B recommendation) states it is "reasonable to use prasugrel or ticagrelor in preference to clopidogrel" for most patients with acute coronary syndromes treated with or without stenting ([@MCS003731BONC40]). Along these lines, the rate of prescribing either prasugrel or ticagrelor is approaching the rate of prescribing clopidogrel for these patients ([@MCS003731BONC11]). Similar use of next-generation antiplatelet agents has not yet occurred for stroke prevention. With the consequences of antiplatelet therapy being so profound in neurological disease---both beneficial and potentially harmful---further consideration should be given to investigating the potential of individualized regimens.

Several recent transformational advances in medicine have occurred to facilitate the potential for individualized pharmacologic stroke prevention. In terms of discovery potential, the ability to perform high-throughput, large-scale sequencing in a large population is now a reality. In a study of more than 50,000 patients, whole-exome sequencing was performed and correlated with phenotypes extracted from the clinical medical record to discover novel disease-associated variants ([@MCS003731BONC12]). For neurovascular patients, this powerful technique has the potential to survey the entire genomic landscape in an unbiased fashion. Exome sequencing has been applied in limited fashion to identify novel variants associated with platelet reactivity to clopidogrel, an approach that may be fruitful in larger studies ([@MCS003731BONC61]; [@MCS003731BONC41]). This is an attractive approach, linking genetic data with platelet function assays and clinical outcomes to study a population comprehensively, forgoing the need to make a priori inferences about clinical significance.

Beyond discovery, genomic characterization is also poised to transform therapeutic decision-making for neurovascular patients. In a proof-of-principle study, investigators randomized patients to genotype-based or clinically based (typical) dosing of warfarin to prevent venous thromboembolism after orthopedic surgery ([@MCS003731BONC18]). Because warfarin has variation in bioactivity secondary to different genotypes, similar to antiplatelet agents like clopidogrel, it was hypothesized that genotype-based dosing would optimize treatment within the therapeutic index. Indeed, the genotype-based dosing group experienced a lower combined risk of bleeding, international normalized ratio of 4 or greater, venous thromboembolism, or death. This idea was recently replicated for clopidogrel in cardiovascular disease, in which patients were treated with prasugrel or ticagrelor in the event of pharmacogenetic evidence of clopidogrel resistance ([@MCS003731BONC7]). Patients with predicted clopidogrel resistance, assessed by *CYP2C19* genotyping for loss-of-function alleles, who were treated with an alternative antiplatelet agent experienced adverse thrombotic events at a lesser rate than those treated with clopidogrel and at a similar rate to those without clopidogrel resistance who were treated with clopidogrel. In similar fashion, could genotype-based antiplatelet selection improve the safety and efficacy of treatment in neurovascular patients? Further study is needed ([Table 5](#MCS003731BONTB5){ref-type="table"}).

###### 

Ongoing clinical trials investigating pharmacogenomics in antiplatelet use

  Clinicaltrials .gov ID   Study title (Location)                                                                                                                                             Estimated year of completion   Enrollment   Summary
  ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------ ------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCT02955121              IU Health Krannert Personalized Medicine Study                                                                                                                     2018                           270          Patients undergoing PCI randomized to receive genotyping for *CYP2C19* LOF alleles versus no genotyping. Use of genotyping to guide antiplatelet use is optional.
  NCT01930773              Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST, Hungary/Poland)                                          2018                           150          Patients undergoing PCI randomized to genotype-based (*CYP2C19* LOF alleles) versus phenotype-based (platelet function assay) determination of clopidogrel resistance for treatment with prasugrel.
  NCT01641510              PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants (Korea)                                                                          2018                           70           Patients with ACS and *CYP2C19* LOF alleles randomized to high loading dose + standard maintenance dose clopidogrel versus half-dose prasugrel.
  NCT01761786              Cost-effectiveness of Genotype-Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics; multiple European sites)   2019                           2700         Patients undergoing PCI randomized to receive genotyping for *CYP2C19* LOF alleles versus no genotyping. Patients in genotyping arm receive prasugrel/ticagrelor if LOF *CYP2C19* alleles, otherwise clopidogrel. Patients in control arm receive prasugrel/ticagrelor.
  NCT02724319              Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy (Florida)                                                                                       2019                           2500         Patients undergoing cardiac catheterization receive buccal swab genotyping for *CYP2C19* LOF alleles with optional genotype-guided therapy for patients receiving PCI.
  NCT02065479              A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function (Florida)                                   2019                           100          Patients undergoing PCI with *CYP2C19* LOF alleles randomized to receive prasugrel versus ticagrelor.
  NCT03489863              Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study (Florida)                                                                2019                           50           Patients with CAD not undergoing PCI with CYP2C19 LOF alleles randomized to receive prasugrel versus ticagrelor.

Certain challenges arise when translating genetic discovery to clinical practice for stroke prevention. For one, robust genotype--phenotype associations do not yet exist with regard to genotype and response to antiplatelet therapy in this specific population. Given the widespread use of platelet function assays (albeit inconsistent in frequency and with different techniques) and the availability to perform follow-up surveillance neuroimaging, clinical data can be collected to bridge the understanding between genetic variation and clinical outcomes. Additionally, the umbrella of neurovascular disease encompasses a heterogeneous group of pathophysiology, from cervical carotid artery stenosis to flow-diverting stents for giant aneurysms, and identifying patients at similar risk/mechanism for thrombosis is essential.

Although current clinical practice for stroke prevention is primarily empiric antiplatelet therapy with aspirin and/or clopidogrel, a large proportion of the population with genetic variation resulting in varied drug bioactivity exists. Whether this variation stems from genetic ancestry or otherwise ([@MCS003731BONC34]), genotyping is essential for a better understanding. For patients undergoing interventional procedures, ex vivo platelet function assays used to tailor dosing regimens to meet arbitrary therapeutic windows is fraught with individual experimentation. In addition to purely empiric treatment and functional assay--guided treatment, a third potential pathway to base treatment decisions is now available: genotype-guided treatment.
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